News & Updates

Olanzapine a favourable alternative to dexamethasone for CINV

27 Sep 2021 by

Olanzapine administered at a dose of 5 mg was noninferior to dexamethasone and is associated with fewer adverse effects than dexamethasone for chemotherapy-induced nausea and vomiting (CINV), according to data presented at ESMO 2021.

Olanzapine a favourable alternative to dexamethasone for CINV

27 Sep 2021

ICG fluorescence imaging improves intraoperative judgement during bowel obstruction surgery

26 Sep 2021

Indocyanine green (ICG) fluorescence imaging can help visualize intestinal blood flow better during laparoscopic surgery for strangulated bowel obstruction, a recent study has found.

ICG fluorescence imaging improves intraoperative judgement during bowel obstruction surgery

26 Sep 2021

Cost, convenience main barriers to colonoscopy screening for CRC

25 Sep 2021 by

Perceived barriers to healthcare, such as cost and inconvenience, discourage patients with positive faecal immunochemical test (FIT) results from undergoing follow-up colonoscopy for colorectal cancer (CRC) screening, according to a recent Singapore study.

Cost, convenience main barriers to colonoscopy screening for CRC

25 Sep 2021

Sintilimab-chemo a new first-line treatment alternative for GI cancers?

22 Sep 2021 by

Interim results of two phase III ORIENT trials presented at ESMO 2021 underscore the potential of a combination regimen comprising the PD-1 inhibitor sintilimab and chemotherapy (CT) as a first-line therapeutic alternative for gastrointestinal cancers, particularly advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (SCC) and gastric/gastroesophageal junction (G/GEJ) adenocarcinoma.

Sintilimab-chemo a new first-line treatment alternative for GI cancers?

22 Sep 2021

Ultraprocessed food intake may promote Crohn’s disease

20 Sep 2021

Eating a higher amount of ultraprocessed food appears to raise the risk of developing Crohn’s disease, as suggested in a study.

Ultraprocessed food intake may promote Crohn’s disease

20 Sep 2021

Family history of Barrett's oesophagus, OAC a strong risk factor for each disease

17 Sep 2021

Individuals with a family history of Barrett's oesophagus or oesophageal adenocarcinoma (OAC) are at risk of developing the said diseases, according to the results of a systematic review and meta-analysis.

Family history of Barrett's oesophagus, OAC a strong risk factor for each disease

17 Sep 2021

PEG placement-related bleeding risk minimal in patients on uninterrupted antithrombotic therapy

16 Sep 2021

Patients on uninterrupted periprocedural antithrombotic therapy have a negligible risk of significant bleeding associated with the placement of a percutaneous endoscopic gastrostomy (PEG) tube, a recent study has shown.

PEG placement-related bleeding risk minimal in patients on uninterrupted antithrombotic therapy

16 Sep 2021

Vedolizumab safer than anti-TNFs for older IBD patients

16 Sep 2021

In the treatment of older patients with inflammatory bowel disease (IBD), vedolizumab is linked to a lower risk of infection-related hospitalization compared with antitumour necrosis factor-α (anti-TNF) agents, according to a study.

Vedolizumab safer than anti-TNFs for older IBD patients

16 Sep 2021

Higher maintenance adalimumab levels tied to achievement of remission targets in IBD

15 Sep 2021

Clinical remission, endoscopic remission, and biomarker normalization show a positive association with adalimumab trough levels in patients with inflammatory bowel disease (IBD), reports a study. Moreover, adalimumab levels of ≥8.25 μg/mL correlate with deep remission.

Higher maintenance adalimumab levels tied to achievement of remission targets in IBD

15 Sep 2021

Vonoprazan bests PPIs in relieving GERD symptoms in latest meta-analysis

14 Sep 2021 by

The potassium-competitive acid blocker vonoprazan appears to be more effective than proton pump inhibitors (PPIs) in healing severe erosive esophagitis and relieving the symptoms of gastroesophageal reflux disease (GERD), according to a meta-analysis presented at APDW 2021.

Vonoprazan bests PPIs in relieving GERD symptoms in latest meta-analysis

14 Sep 2021

News & Updates

Filter by Specialty:

Specialty:

Olanzapine a favourable alternative to dexamethasone for CINV

Olanzapine a favourable alternative to dexamethasone for CINV

ICG fluorescence imaging improves intraoperative judgement during bowel obstruction surgery

ICG fluorescence imaging improves intraoperative judgement during bowel obstruction surgery

Cost, convenience main barriers to colonoscopy screening for CRC

Cost, convenience main barriers to colonoscopy screening for CRC

Sintilimab-chemo a new first-line treatment alternative for GI cancers?

Sintilimab-chemo a new first-line treatment alternative for GI cancers?

Ultraprocessed food intake may promote Crohn’s disease

Ultraprocessed food intake may promote Crohn’s disease

Family history of Barrett's oesophagus, OAC a strong risk factor for each disease

Family history of Barrett's oesophagus, OAC a strong risk factor for each disease

PEG placement-related bleeding risk minimal in patients on uninterrupted antithrombotic therapy

PEG placement-related bleeding risk minimal in patients on uninterrupted antithrombotic therapy

Vedolizumab safer than anti-TNFs for older IBD patients

Vedolizumab safer than anti-TNFs for older IBD patients

Higher maintenance adalimumab levels tied to achievement of remission targets in IBD

Higher maintenance adalimumab levels tied to achievement of remission targets in IBD

Vonoprazan bests PPIs in relieving GERD symptoms in latest meta-analysis

Vonoprazan bests PPIs in relieving GERD symptoms in latest meta-analysis